No Data
No Data
Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests
Myriad Genetics (MYGN) and Personalis (PSNL) agreed to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease to boost patient access to MRD testing.The
Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Express News | Tempus AI, Inc. Reports 15.1% Stake in Personalis Inc as of July 3, 2024-SEC Filing
Express News | Ravi Mhatre - Will Seek to Engage in Dialogue With Personalis’ Board and/or Management About Strategic Opportunities to Maximize Co's Shareholder Value
Express News | Personalis- Co, Foresight to Settle Litigation Pending in U.S. Federal District Court, Iprs Pending Before U.S. Ptab in Each Case Related to Patents